EPHB6 is altered in 2.03% of all cancers with high grade ovarian serous adenocarcinoma, melanoma, bladder urothelial carcinoma, conventional glioblastoma multiforme, and gastric adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in EPHB6 are EPHB6 Mutation (2.03%), EPHB6 R920C (0.24%), EPHB6 A562T (0.26%), EPHB6 A903D (0.85%), and EPHB6 A990G (0.39%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.